CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020 MUNICH, Germany, June 18, 2020 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that two abstracts identifying a novel...